<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03295214</url>
  </required_header>
  <id_info>
    <org_study_id>1098410</org_study_id>
    <nct_id>NCT03295214</nct_id>
  </id_info>
  <brief_title>Acetaminophen Given Per Os and Intravenous in Sinus Surgery</brief_title>
  <official_title>A Prospective Clinical Trial Evaluating the Post-Operative Analgesic Effects of Acetaminophen Given Per Os and Intravenous</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the Visual Analog Score (VAS) for pain
      within the post-operative setting and determine if there is a statistically significant
      difference between the VAS for PO or IV acetaminophen. It is expected that in doing so the
      investigators can produce the maximal amount of pain relief after surgery while making
      conscientious monetary decisions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional Endoscopic Sinus Surgery (FESS) is one of the most common Ear Nose and Throat
      Surgeries done in the United States annually. This procedure can vary from intense to
      moderate pain and as such it is difficult to properly gauge and treat postoperative pain in
      these patients. Commonly used in these cases, opioid drugs are given to provide adequate
      analgesia, however higher opioid usage is observed to cause increased Post-Anesthesia Care
      Unit (PACU) stays, respiratory complications and Postoperative Nausea and Vomiting (PONV).
      Acetaminophen is commonly used as an adjunct in these circumstances because of its opioid
      sparing properties.

      Acetaminophen is a synthetic nonopioid p-aminophenol derivative available over the counter.
      Its properties include analgesic and antipyretic qualities and it is listed on the world
      health organization's list of essential medicines. The potential risks include liver damage,
      skin reactions and drug interactions when used with blood thinners at high doses.
      Acetaminophen has been extensively researched, in vitro and in vivo studies have found the
      drug to be safe when used at proper doses. Recently intravenous use of acetaminophen has
      gained popularity due to ease of use and ability to be given intraoperatively. This form of
      acetaminophen, although convenient, is around sixty two times the cost of oral acetaminophen.
      Due to this increased cost it is imperative that the investigators compare the two routes of
      administration in order to determine if the additional cost is justified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>0-1 hour</time_frame>
    <description>First VAS pain score applied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Use</measure>
    <time_frame>24 hours</time_frame>
    <description>Postoperative opioid consumption for pain control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in PACU</measure>
    <time_frame>3-5 hours</time_frame>
    <description>Time required to be admitted and discharged home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>1-2 hours</time_frame>
    <description>Second VAS pain score applied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>2-3 hours</time_frame>
    <description>Third VAS pain score applied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>24 hours</time_frame>
    <description>Last VAS pain score applied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PONV</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of PONV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Acetaminophen</condition>
  <arm_group>
    <arm_group_label>Acetaminophen 975mg Per Os</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>975mg of Acetaminophen given by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen 1000mg Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg of Acetaminophen given intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen given for pain relief</description>
    <arm_group_label>Acetaminophen 975mg Per Os</arm_group_label>
    <arm_group_label>Acetaminophen 1000mg Intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to participate

          -  Undergoing FESS surgery at Massachusetts Eye and Ear (MEE)

          -  Over the age of 18 during time of surgery

          -  Weighing over 50kg

        Exclusion Criteria:

          -  Severe hepatic impairment or active liver disease

          -  Known hypersensitivity to acetaminophen or to any excipients in the intravenous
             formulation

          -  chronic opioid use

          -  chronic pain

          -  alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iuliu Fat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEEI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex Ciaramella, BS</last_name>
    <phone>6175733276</phone>
    <email>alex_ciaramella@meei.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iuliu Fat, MD</last_name>
    <phone>617-573-3380</phone>
    <email>iuliu_fat@meei.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Ciaramella, BS</last_name>
      <phone>617-573-3276</phone>
      <email>alex_ciaramella@meei.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carroll NV, Miederhoff PA, Cox FM, Hirsch JD. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J Clin Anesth. 1994 Sep-Oct;6(5):364-9.</citation>
    <PMID>7986507</PMID>
  </reference>
  <reference>
    <citation>DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998 Jan;86(1):102-6.</citation>
    <PMID>9428860</PMID>
  </reference>
  <reference>
    <citation>Fenlon S, Collyer J, Giles J, Bidd H, Lees M, Nicholson J, Dulai R, Hankins M, Edelman N. Oral vs intravenous paracetamol for lower third molar extractions under general anaesthesia: is oral administration inferior? Br J Anaesth. 2013 Mar;110(3):432-7. doi: 10.1093/bja/aes387. Epub 2012 Dec 6.</citation>
    <PMID>23220855</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Luliu Fat</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Functional Endoscopic Sinus Surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

